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Predictive value of urinary micro-cholesterol (mCHO) levels in
patients with progressive glomerular disease.
Background. Trace amounts of lipids are present in the urine
of patients with glomerular disease, raising the possibility that
the excess lipids reabsorbed by tubule cells may be toxic to these
cells. In the present study, we assessed the prognostic value
of micro-cholesterol (mCHO) levels in patients with chronic
glomerular disease.
Methods. The urinary mCHO levels of healthy subjects and
patients with chronic kidney disease were measured by the enzy-
matic cholesterol cycling (ECC) method with a minimum detec-
tion level of 0.10 × 10−3 mmol/L. First, the urinary mCHO levels
of healthy subjects and 320 patients with various glomerular
diseases with proteinuria >1000 mg/gCr were measured. Sec-
ond, correlations of urinary mCHO levels with those of vari-
ous other molecules, including albumin, IgG, IgM, transferrin,
phospholipid, a 1-microglobulin (a 1MG), Apo A1, Apo A2, and
Apo B, and urinary fatty body counts, were determined. Third,
urinary mCHO, total protein (TP), albumin, and N-acetyl-
b-D-glucosaminidase (NAG) levels were measured longitudi-
nally over 12 months (20.5 ± 5.8 months) in 68 nondiabetic
patients with impaired renal function [serum creatinine (Cr)
≥1.5 mg/dL]. Correlations of the concentrations of urinary pa-
rameters in the initial 3-month period with the slopes of the
reciprocal of creatinine versus time for the entire follow-up pe-
riod were assessed by the ROC method and multiple regression
analysis.
Results. Urinary mCHO levels of the healthy subjects were
0.06 to 0.72 mg/gCr for males and 0.16 to 2.34 mg/gCr for fe-
males. Urinary mCHO levels in subjects with minimal change
nephrotic syndrome were significantly lower than those in the
patients with other glomerular diseases with massive protein-
uria. Urinary mCHO levels correlated significantly with Apo
A1 and Apo A2 levels, but not with urinary Apo B levels, in
the latter subjects. The correlation coefficient of urinary fatty
body counts (a marker of lipoprotein loading tubulopathy) with
mCHO was higher than those with TP, albumin, IgG, IgM, and
a 1MG. The urinary mCHO elevation was significantly greater
in patients who had a nonselective index of proteinuria than in
those with a highly or moderately selective index. In nondia-
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betic patients with impaired renal function, the urinary mCHO
level had a higher predictive value for rapid decline of renal
function than TP, albumin, or NAG.
Conclusion. The urinary cholesterol level corresponds to the
magnitude of urinary HDL excretion, and correlates with the
degree of lipoprotein loading tubulopathy. Measurement of uri-
nary mCHO by the ECC method is a simple and useful tool for
predicting progression of chronic glomerular disease.
There is compelling evidence that total urinary protein
excretion has value in predicting renal function decline
in most forms of glomerular disease [1–3]. A correla-
tion has been found between the amount of proteinuria
and the degree of tubulointerstitial damage, which re-
flects some toxicity of proteinuria on tubular cells [4, 5].
It seems unlikely that albumin, a major component of uri-
nary protein, per se, is damaging to tubular cells because
patients with minimal change nephrotic syndrome, which
is characterized by heavy and sometimes prolonged al-
buminuria, do not develop tubulointersitital damage [6].
Sustained severe proteinuria, mostly albuminuria, with-
out glomerular abnormalities has not been found to cause
interstitial fibrosis in an animal model [7]. Certain plasma
proteins other than albumin, such as complements, trans-
ferrin, iron, IgG, and lipoprotein in the tubular lumen, are
thus thought to be toxic to tubule cells [8–15]. To date,
however, no single feature or component of proteinuria
has been identified as being responsible for this toxicity.
Small amounts of lipid appear in the urine of healthy
subjects, whereas a considerable amount of high-density
lipoprotein and smaller amounts of other lipoproteins are
present in the urine in glomerular disease [16]. Because
filtered lipoprotein is reabsorbed and subsequently me-
tabolized in tubular cells [17], and modified lipoproteins
are toxic to human proximal tubule cells in culture [18], it
has been postulated that lipoprotein filtration and reup-
take by tubule cells play important roles in tubular injury
[16]. We therefore hypothesized that urinary lipid levels
might be a better predictor of the progression of protein-
uric glomerular disease than total urinary protein excre-
tion. However, because urinary lipid levels are very low,
the method used for plasma samples cannot be applied to
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the measurement of urinary lipids. The enzymatic choles-
terol cycling (ECC) method is a recently developed highly
sensitive assay for detecting trace amounts of lipids [19],
which enabled us to measure trace lipid levels in the urine.
In the present study, we measured urinary mCHO levels
in normal subjects and patients with chronic glomeru-
lar disease, and then examined the predictive value of
mCHO for progressive renal function decline in com-
parison with urinary total protein (TP), albumin, and N-
acetyl-b-D-glucosaminidase (NAG).
METHODS
Subjects
Normal urine. Spot urine samples were obtained from
174 healthy volunteers (105 males and 69 females). Vol-
unteers without kidney disease based on negative urinary
dipstick tests for proteinuria and hematuria and normal
serum creatinine (Cr) levels were considered healthy.
Daily drift and influence of the menstrual cycle were as-
sessed in two healthy volunteers.
Urine in kidney disease. To compare urinary mCHO
levels, freshly voided spot urine samples were obtained
from 320 patients with various glomerular diseases in
which the urinary total protein (TP) concentration was
higher than 1000 mg/gCr. The patients’ diseases were
IgA nephropathy (IgAN, N = 70), rapidly progressive
glomerulonephritis (RPGN, N = 37), diabetic nephropa-
thy (DN, N = 97), focal and segmental glomerular sclero-
sis (FSGS, N = 26), membranous nephropathy (MN, N =
39), membranoproliferative glomerulonephritis (MPGN,
N = 13), minimal change nephrotic syndrome (MCNS,
N = 24), and diffuse proliferative lupus nephritis (DPLN,
N = 14).
We used 144 urine samples to calculate the correla-
tion coefficients for the relationships of urinary mCHO
to other parameters, including Apo A1, Apo A2, Apo B,
albumin, IgG, transferrin, and phospholipids, by multiple
regression analysis.
For 105 patients, correlation coefficients were calcu-
lated for the relationships of urinary fatty body counts
to urinary parameters represented by various molecules,
including mCHO, IgG, IgM, TP, albumin, and a1-
microglobulin (a1MG).
In addition, the selective index (SI) was calculated in
132 patients according to the Cameron and Blandford
method [20] using the following formula:
SI = uIgG
sIgG
× sTransferrin
uTransferrin
Proteinuria was considered nonselective if the SI was
≥0.2, and moderately selective or highly selective if the
SI was (0.2 [21].
Serial assays for mCHO and other urinary parameters in
impaired renal function
To assess the correlations between the rapidity of renal
function decline and the urinary parameters of mCHO,
TP, albumin, and NAG, monthly urine and blood samples
were prospectively obtained for more than 12 months
(12–24 months, mean 20.3 months) from 70 patients with
impaired renal function (serum Cr ≥1.5 mg/dL). To as-
sess the predictive values of urinary parameters, corre-
lations between the means of urinary levels during the
initial 3-month period and the value of the reciprocal of
serum Cr versus time plots during the entire observa-
tion period were examined by the nonparametric receiver
operating characteristic (ROC) method and multiple re-
gression analysis. The patients’ diseases were IgAN (N =
32), FSGS (N = 11), hypertensive nephrosclerosis (N =
19), reflux nephropathy (N = 5), MN (N = 1), MPGN
(N = 1), and Alport’s syndrome (N = 1).
Freshly voided spot urine samples were used for this
prospective study and for the measurement of urinary
fatty body counts. For other studies, stocked urine sam-
ples, which had been stored at −70◦C, were used.
All patients and volunteers provided informed consent
for the collection of samples.
To measure urinary concentrations, we used spot urine
samples rather than collected urine because most of our
subjects were outpatients, in whom accurate 24-hour
urine collection is often impractical and inconvenient [22,
23], and because the reliability of the spot urine protein-
Cr ratio as a predictor of 24-hour proteinuria has been
established [23–25]. Similarly, using the ratios of albumin,
IgG, and a1MG to Cr in spot urine samples for diagnostic
purposes has been advocated [26].
Measurement of mCHO levels
Urinary mCHO levels were measured by the ECC
method using cholesterol ester hydrolase (CEH) and
cholesterol dehydrogenase [19]. Briefly, cholesterol es-
ters are hydrolyzed to free cholesterol and fatty acids
by CEH, the free cholesterol reversibly changes to its
oxidized form, and the cycling reaction is repeated sev-
eral times in the presence of thio-NAD and NADH. The
amount of thio-NADH produced by this ECC method
is calculated from the change in absorbance per minute,
and the amount corresponds to the cholesterol level in the
sample. This ECC method was performed on a Hitachi-
7070 automatic analyzer (Hitachi, Tokyo, Japan) by rate
assay with absorbance set at 405/505 nm. TP, Alb, NAG,
and Cr were simultaneously measured at 660/750 nm,
340/700 nm, 340/600 nm, and 546/660 nm, respectively.
Fatty body quantification
A 5 mL sample of freshly voided urine was cen-
trifuged for 10 minutes at 1500 rpm. The supernatant was
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aspirated, and the sediment was washed with 0.01 mol/L
phosphate-buffered saline (PBS), pH 7.2. After elimi-
nating red blood cells by hypotonic lysis, the sediment
was resuspended in PBS. The cells in 0.1 mL suspensions
were cytocentrifuged onto poly-L-lysine-coated micro-
scopic slides by centrifugal force (500 rpm, 5 minutes)
using Cytospin 3 (Shandon Scientific Limited, Cheshire,
England). The slides were then air dried for 15 minutes,
reacted with oil red O (ORO) for 10 minutes at room
temperature, and washed in running tap water [27].
Assays of other urinary parameters
The reagents used were Apo A-I Auto N (Daiichi Pure
Chemicals, Tokyo, Japan), Apo A-II Auto N (Daiichi
Pure Chemicals), Apo B Auto N (Daiichi Pure Chem-
icals), m-TP Reagent K (Sysmex, Kobe, Japan), m-
ALB Reagent K (Sysmex), N-Assay NAG (Nittobo,
Tokyo, Japan), IgG Reagent ND (Sysmex), IgM Reagent
ND (Sysmex), Tf Reagent ND (Sysmex), LX Reagent
Eiken a1-M-II (Eiken Chemical, Tokyo, Japan), and PL
Reagent A (Sysmex). Each assay was carried out on an
automatic analyzer following the manufacturer’s instruc-
tions.
Statistical analysis
All data are expressed as mean ± SD. The correla-
tion analysis was performed using Pearson’s correlation
coefficients (nonparametric). A P value < 0.05 was con-
sidered significant. Correlations were tested using Spear-
man’s correlation coefficients. ROC plots were devised
as described by Zweig and Campbell [28]. The statistical
analysis for ROC curves was performed by the Jackknife
method [29] using LABMRMC1.0B, and other statisti-
cal analyses were performed using SPSS (version 11.0 J,
Chicago, IL, USA).
RESULTS
Urinary mCHO level of normal subjects
Measurable amounts of mCHO were detected by the
ECC method in all subjects (minimum 0.007 mg/dL). The
nonparametric method revealed the normal range of uri-
nary mCHO concentrations to be higher in female than
in male subjects: 0.06 to 0.72 mg/gCr in males and 0.16
to 2.34 mg/gCr in females. The normal range of urinary
TP values in the same samples was 4 to 130 mg/gCr in
males and 8 to 178 mg/gCr in females. Urinary mCHO
levels were not influenced by either age or menstrual cy-
cle (data not shown).
Urinary mCHO levels of glomerular disease patients
Although all patients had proteinuria >1000 mg/gCr,
the urinary mCHO levels were within normal range in
Table 1. Urinary mCHO levels in various forms of glomerular
disease patients with proteinuria of >1000 mg/gCr
mCHO (mg/gCr) No. of patients within
Disease N Mean ± SD normal range N (%)
IgAN 70 3.19 ± 2.25a 10 (14.3)
DN 97 12.55 ± 17.40a 2 (2.1)
FSGS 26 10.60 ± 14.97a 3 (11.5)
MCNS 24 2.01 ± 1.40 5 (20.8)
MN 39 5.28 ± 4.73a 5 (12.8)
MPGN 13 7.58 ± 5.31b 0 (0)
RPGN 37 13.87 ± 15.23b 2 (5.4)
DPLN 14 10.11 ± 9.98b 4 (28.6)
Abbreviations are: IgAN, IgA nephropathy; DN, diabetic nephropathy; FSGS,
focal and segmental glomerular sclerosis; MCNS, minimal change nephrotic
syndrome; MN, membranous nephropathy; MPGN, membranoproliferative
glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; DPLN,
diffuse proliferative lupus nephritis.
aP < 0.01 vs. MCNS; bP < 0.001 vs. MCNS.
Table 2. Correlations between urinary mCHO levels and other
parameters
R SE lg/dL/uCr
Apo A1 0.569 14.2
Apo A2 0.677 12.7
Apo B 0.029 17.3
Albumin 0.268 16.7
IgG 0.728 11.9
Transferrin 0.581 14.1
Phospholipid 0.238 16.8
R, correlation coefficient; SE, standard error.
more than 20% of patients with MCNS and DPLN. On
the other hand, increased urinary mCHO levels were ob-
served in most patients with DN, MPGN, and RPGN.
In patients with MCNS, mCHO levels were signif-
icantly lower than those of patients with any other
glomerular diseases (Table 1).
Correlations of urinary mCHO levels with other
parameters
The correlations of urinary mCHO with other pa-
rameters were investigated in 144 patients with vari-
ous glomerular diseases. The correlation coefficients of
mCHO with Apo A1and ApoA2 were high, whereas no
correlation was observed with Apo B. The correlation co-
efficient of mCHO with IgG was higher than those with
albumin, transferring, and phospholipid (Table 2).
Correlations of urinary fatty body counts with urinary
parameters
Because urinary fatty body counts could be considered
to reflect the degree of lipoprotein-induced tubular in-
juries [27], we examined the correlation between urinary
fatty body counts and urinary parameters.
The correlation coefficient value with log transformed
urinary fatty body counts per 5 mL urine sample was
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Fig. 1. Correlations of urinary fatty body
counts (ORO positive cells) with other uri-
nary parameters.
highest for the urinary mCHO concentration, followed
by IgG, IgM, TP, albumin, and a1MG (Fig. 1). As there
was an outlier on the mCHO/ORO graph, we reana-
lyzed the data without this outlier, and reconfirmed that
the highest correlation coefficient was for mCHO (R:
mCHO 0.5670, IgG 0.4857, IgM 0.4158, TP 0.3023, al-
bumin 0.2555, a1MG 0.2621).
SI and urinary parameters
The concentrations of urinary parameters were com-
pared in relation to SI. The concentrations of all urinary
parameters examined were significantly higher in patients
with nonselective proteinuria (SI ≥0.2) than in those with
highly or moderately selective proteinuria (SI <0.2).
The degree of difference between two categories iden-
tified by P value was most pronounced for IgG, followed
by mCHO, TP, albumin, transferrin, IgM, and a1MG
(Table 3).
Predictive value of mCHO
The value of mCHO in predicting progressive renal
function decline was assessed in comparison with the
predictive values of TP, albumin, and NAG. The means
during the initial 3-month observation period were eval-
uated as predictors of subsequent progressive renal de-
cline during the entire follow-up period. Considering pre-
vious reports [30–32], “rapid decline of renal function”
was defined as a slope of −1/Cr/month >0.004 dur-
ing the total observation period. Initially, 70 patients in
total with nondiabetic chronic renal diseases were en-
rolled, but two were excluded from the analysis because
Table 3. Urinary concentrations of various markers in two groups
based on SI
SI <0.2 SI ≥0.2
N = 80 N = 52
mg/gCr Mean ± SD Mean ± SD P value
mCHO 2.80 ± 1.58 13.61 ± 10.52 1.73 × 10−15
IgM 2.3 ± 6.4 16.5 ± 26.0 6.87 × 10−6
IgG 36.2 ± 86.9 478.7 ± 367.8 1.15 × 10−18
Transferrin 105.4 ± 80.1 180.0 ± 82.6 8.96 × 10−7
Albumin 2002.3 ± 1208.2 4373.2 ± 2105.3 1.87 × 10−13
a1MG 31.4 ± 33.8 51.5 ± 29.1 5.80 × 10−4
Total protein 2444.8 ± 1534.8 5654.4 ± 2724.8 1.72 × 10−14
Abbreviations are: SI, selectivity index; a 1MG, a 1-microglobulin.
of acute exacerbation of chronic renal failure due to a pri-
mary glomerular disease flare-up during follow-up. Con-
sequently, correlations of the concentrations of urinary
parameters in the initial 3-month observation period with
the slopes of the reciprocal of Cr versus time for the entire
follow-up period were assessed in 68 patients (44 males
and 24 females). Both an angiotensin-converting enzyme
(ACE) inhibitor and an angiotensin II-receptor blocker
(ARB) were administrated in 21 patients, ACE inhibitor
alone and ARB alone in 4 and 36 patients, respectively.
No patients were treated with steroids or other immuno-
suppressive therapy during follow-up. Four patients (2
IgAN, 1 FSGS, and 1 nephrosclerosis) reached end-stage
renal failure requiring regular dialysis therapy during
follow-up.
The initial serum Cr levels of 68 patients were 2.52 ±
0.94 mg/dL. The mean values and SD of urinary pa-
rameters at the time of entry were as follows: mCHO
1.74 ± 1.75 mg/gCr, TP 1089 ± 942.9 mg/gCr, albumin
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Fig. 2. Correlation of serum cholesterol with urinary mCHO concen-
tration.
925.1 ± 838.3 mg/gCr, and NAG 12.3 ± 7.1 IU/gCr. Uri-
nary mCHO levels did not correlate with serum choles-
terol levels (Fig. 2).
The −1/Cr/month levels during the entire follow-
up period were higher than 0.004 in 15 of 44 male pa-
tients, and 10 of 24 female patients. The ROC plots
for mCHO, TP, albumin, and NAG using an end point
of −1/Cr/month >0.004 are presented in Figure 3.
Although the difference between ROC curves by the
Jackknife method did not reach statistical significance
(possibly due to the number of subjects being insuffi-
cient), the area under the curve was highest and the stan-
dard error lowest for mCHO in both males and females.
The correlations between the rapidity of renal function
deterioration defined by the slope of 1/Cr versus time dur-
ing the entire observation period (20.5 ± 5.8 months) and
urinary parameters in terms of means of the values during
the initial three months, and means of values throughout
the observation period determined by multiple regression
analysis in 68 patients with chronic renal failure are shown
in Table 4. The highest correlation coefficient among the
urinary parameters, including mCHO, TP, albumin, and
NAG, was with mCHO in both genders. Furthermore, in
males, the P value of the correlation coefficient (R) of
−1/Cr/m for the entire follow-up period with the initial
3-month average of mCHO was lower than those with
TP, albumin, and NAG.
DISCUSSION
Amounts of urinary cholesterol were measurable by
the ECC method in both the kidney disease patients
and healthy subjects. Urinary mCHO levels correlated
significantly with urinary Apo A1 and Apo A2 levels,
but not with urinary Apo B levels, indicating the major
component of urinary mCHO to be high-density lipopro-
tein (HDL), which is consistent with earlier reports [15].
Most HDL particles have a larger radius (2.5–6.0 nm)
than albumin (3.6 nm). However, a few HDL particles
may pass through the glomerular filtration barrier even
in healthy subjects, because glomerular basement mem-
brane (GBM) pores are thought to have a diameter on
the order of 3 nm. Cubilin is an HDL receptor that
is abundantly expressed in proximal tubule cells [33],
which may account for passage of HDL particles through
the glomerular filtration barrier under physiologic con-
ditions. Therefore, it is not surprising that small amounts
of mCHO were detected in the healthy subjects, and an
increase in urinary mCHO excretion would presumably
reflect a breakdown of the glomerular filtration barrier.
The ECC method applied in the present study with a
lower detection limit of 0.10 × 10−3 mmol/L was sensitive
enough to measure urinary cholesterol levels of healthy
subjects. There were no significant gender differences in
urinary Apo A1 levels among healthy subjects in a previ-
ous study by Gomo and Henderson [34]; however, among
our healthy subjects, urinary mCHO levels were higher
in females than in males.
Although the reason for this discrepancy is unclear, the
number of normal subjects in Gomo’s study was rather
small, 25 males and 25 females, and marked variability in
concentrations was observed within each gender groups.
The following possibilities may explain the gender differ-
ences in urinary mCHO concentrations: (1) susceptibility
of females to silent urinary tract infections, which may in-
fluence their urinary mCHO concentration; and (2) gen-
der differences in HDL subclass. The HDL3 to HDL2
ratio is lower in females than in males [35], and HDL3 has
been demonstrated to be more effectively reabsorbed by
renal tubular cells than HDL2 [36]. Moreover, Short et
al [37] found a statistically significant increase in serum
HDL3, and a decrease in serum HDL2 in male patients
with nephropathy.
There is no cross-reactivity with urinary pregnanediol
or pregnanetriol in the ECC assay. Although the ECC as-
say system is affected by testosterone and estradiol, the
urinary concentrations of these steroid hormones are too
low to alter the mCHO concentration. Nor were urinary
mCHO levels affected by the menstrual cycle or admin-
istration of high-dose steroids (our preliminary observa-
tions).
Increased urinary excretion of HDL is associated with
poor selectivity of the GBM, and a positive correlation
exists between the amount of HDL in the urine and the
selectivity ratio in proteinuric renal disease [34]. More-
over, proteinuria selectivity has been demonstrated to
have predictive value for functional outcome [21], indi-
cating that some components of nonselective proteinuria
cause tubulointerstitial injury.
In the present study, urinary mCHO levels in MCNS
patients were significantly lower than those in any other
form of proteinuric glomerular disease. Moreover, the
statistical significance of differences between nonselec-
tive proteinuria patients and highly or moderately se-
lective proteinuria patients was greater for mCHO than
IgM, transferrin, albumin, and a1MG.
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Fig. 3. Comparison of receiver-operating
characteristic (ROC) curves in predicting
rapid progression. Rapid progression is
defined as −1/sCr/month >0.004 during the
entire follow-up period.
Table 4. Correlations between rate of functional deterioration and urinary parameters
Total (N = 68) Male (N = 44) Female (N = 24)
Markers Initial 3 monthsa Entire periodb Initial 3 months Entire period Initial 3 months Entire period
mCHO R 0.708d 0.825d 0.499d 0.598d 0.925d 0.925d
SE 0.0052 0.0042 0.0048 0.0044 0.0037 0.0037
UTP R 0.574d 0.760d 0.374c 0.505d 0.874d 0.874d
SE 0.0060 0.0048 0.0051 0.0048 0.0048 0.0048
UAlb R 0.570d 0.747d 0.346c 0.465d 0.872d 0.872d
SE 0.0061 0.0049 0.0052 0.0049 0.0048 0.0048
NAG R 0.621d 0.703d 0.333c 0.343c 0.874d 0.874d
SE 0.0058 0.0052 0.0052 0.0052 0.0048 0.0049
R, correlation coefficient; SE, standard error (−1/Cr/month).
aCorrelation between −1/Cr/month of the entire follow-up period and means of values in the initial 3 months.
bCorrelation between −1/Cr/month of the entire follow-up period and means of values in the entire follow-up period.
cP < 0.05 (vs. −1/Cr/month).
dP < 0.01 (vs. −1/Cr/month).
These findings indicate that increased mCHO levels
correspond to decreased GBM selectivity. Although the
statistical significance of the difference in mCHO with
SI was lower than that of IgG, this is quite reasonable
because SI was calculated based on the clearance of IgG.
There is little doubt that excesses in lipoprotein filtra-
tion and reuptake by tubule cells are a source of toxicity
to tubule cells themselves [16]. Lipid is found in several
forms in the urinary sediment of patients with kidney
disease—as free fat droplets, entrapped in casts, and as
oval fatty bodies. Fatty bodies are present in the urine of
nephrotic syndrome patients with nonselective protein-
uria or chronic renal failure, and their urinary fatty body
counts correlate with the rate of chronic renal failure pro-
gression [27]. Fatty bodies presumably appear in the urine
as a result of lipid-degeneration of tubular epithelial cells.
In earlier studies, we [38] and Bariety et al [39,
40] demonstrated giant macrophages (macrophage-like
cells) to be present within tubular lumens in pro-
gressive glomerular diseases, and the number of these
macrophages correlated with the degree of proteinuria.
Giant macrophages are thought to be transdifferentiated
from podocytes, parietal epithelial cells, and tubular ep-
ithelial cells [39, 40]. One of the characteristic features
of giant macrophages is that they are lipid-laden (ORO-
positive) cells [38]. ORO-positive staining is commonly
observed within tubular epithelial cells, and occasionally
within podocytes and parietal epithelial cells in kidney
biopsy specimens from patients with massive nonselec-
tive proteinuria. Thus, we assumed that the lipoprotein-
loading within epithelial cells is closely related to the
transdifferentiation of giant macrophages. Most urinary
fatty bodies express macrophagic epitopes (identified by
PGM1 and 25F9 monoclonal antibodies). Furthermore,
the number of lipid-laden macrophages (ORO+CD68+
cells) was shown to correlate with the degree of urinary
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protein excretion and the rapidity of renal functional de-
terioration [27].
As we expected, the urinary fatty body counts were
correlated significantly with mCHO levels, and the corre-
lation coefficient value of mCHO with urinary fatty body
counts was higher than those with other parameters, such
as IgG, IgM, TP, albumin, and a1MG (Fig. 1). Because the
mCHO levels of noncentrifuged whole urine samples did
not differ from those in the supernatants of centrifuged
urine samples, urinary mCHO measurements by the ECC
method are minimally influenced by fatty bodies them-
selves (our preliminary observation). Thus, the urinary
mCHO level may indirectly represent the magnitude of
lipoprotein-loading tubulopathy.
It has been well established that increased urinary pro-
tein excretion is associated with a poor outcome in most
forms of glomerular disease [1–3]. However, renal func-
tion remains stable in MCNS patients, even in the pres-
ence of massive proteinuria. The urinary excretions of
high molecular weight proteins such as IgG and IgM were
reported to be good markers of the prognosis of protein-
uric glomerular diseases [15, 41, 42]. In the present study,
we compared the predictive value of mCHO with those of
TP, albumin, and NAG because in Japan these three pa-
rameters are often examined in daily practice for patients
with renal diseases. Further study is needed to elucidate
which urinary marker is superior, IgG, IgM, or mCHO, in
determining the prognosis of glomerular diseases. Cost-
effectiveness must also be taken into consideration.
CONCLUSION
Increases in urinary mCHO were essentially limited to
patients with a poor outcome in contrast to increases in
urinary TP, albumin, and NAG levels. Direct measure-
ment of toxic components in the urine is clearly superior
to measuring urinary total protein as a means of predict-
ing outcome. We therefore conclude that urinary mCHO,
a potential cause of tubular injury, may serve as a good
indicator of the magnitude of lipoprotein-loading tubu-
lopathy, which is closely related to renal outcome.
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